Vertex Pharmaceuticals expands collaboration with Arbor Biotechnologies

Arbor Biotechnologies announced the expansion of an existing strategic collaboration covering in vivo genetic medicines by which Vertex Pharmaceuticals Incorporated will receive rights to Arbor’s novel precision editing technology for up to three diseases. Under the terms of the agreement, Arbor is eligible to receive payments based upon the successful achievement of specified research, development, regulatory and commercial milestones. In addition, Vertex will pay tiered royalties on future net sales of any products that may result from this collaboration. "This expanded collaboration brings us additional access to tools and expertise to help us advance targets of interest across our cell and genetic therapy portfolio," said David Altshuler, M.D., Ph.D., Chief Scientific Officer of Vertex Pharmaceuticals. "We look forward to continuing to work with Arbor as a valued partner as we use scientific innovation to create transformative medicines for people with serious diseases."